Damaged, diseased, abnormal, obstructive, cancerous or undesired neural tissue treated by delivering specialized pulsed electric field (PEF) energy to target tissue areas. In some instances, the target tissue includes a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue. Most brain and spinal cord tumors develop from glial cells. These tumors are sometimes referred to as a group called gliomas. They arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). One difficulty in the treatment of gliomas is that they are behind the blood-brain barrier (BBB) and blood-tumor barrier (BTB) which leads to poor delivery of anti-cancer drugs or immune agents to the tumor-infiltrated brain. Devices, systems and methods are provided that treat the tumor directly, such as by ablation, and optionally transiently disrupt the BBB coupled with adjuvant antibody, biologic, or other pharmaceutical interventions.

An intravascular catheter for nerve activity ablation and/or sensing includes one or more needles advanced through supported guide tubes (needle guiding elements) which expand to contact the interior surface of the wall of the renal artery or other vessel of a human body allowing the needles to be advanced though the vessel wall into the extra-luminal tissue including the media, adventitia and periadvential space. The catheter also includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened needles are advanced to penetrate into the vessel wall. Electrodes at the distal ends of the guide tubes allow sensing of nerve activity before and after attempted renal denervation. In a combination embodiment ablative energy or fluid is delivered to ablate nerves outside of the media.

A system for controlling operation of a radiofrequency treatment device to apply radiofrequency energy to tissue to heat tissue to create lesions without ablating the tissue. The system includes a first treatment device having at least one electrode for applying radiofrequency energy to tissue, a controller including a connector to which a first treatment device is coupled for use, and a generator for applying radiofrequency energy to the electrodes. The controller controls application of energy so that the tissue is thermally treated to create lesions but preventing thermal treatment beyond a threshold which would ablate the tissue.

A medical RF apparatus using an RF pulse and a method of controlling the medical RF apparatus are provided. The medical RF apparatus includes an RF generator, which generates a test pulse for detecting characteristics of tissue, a monitoring unit, which monitors the change in the information on the tissue state while the test pulse is transmitted to the tissue, and a measurement unit, which determines the tissue characteristics of a patient by comparing the values monitored in the monitoring unit with the reference data.

The present invention provides a method for treating a dermatological condition in a subject, comprising administering to the subjects skin a bioactive composition using a microneedle delivery device, wherein the bioactive composition comprises an effective amount of an anesthetic; administering an effective amount of electromagnetic radiation to the subjects skin to induce damage to the epidermis and/or dermis; and optionally administering to the subjects skin an effective amount of a composition to promote wound healing.

Devices and methods for monitoring the temperature of tissue at various locations in a treatment volume during fluid enhanced ablation therapy are provided. In one embodiment, an ablation device is provided having an elongate body, at least one ablation element, and at least one temperature sensor. The elongate body includes a proximal and distal end, an inner lumen, and at least one outlet port to allow fluid to be delivered to tissue surrounding the elongate body. The at least one ablation element is configured to heat tissue surrounding the at least one ablation element. The at least one temperature sensor can be positioned a distance away from the at least one ablation element and can be effective to output a measured temperature of tissue spaced a distance apart from the at least one ablation element such that the measured temperature indicates whether tissue is being heating to a therapeutic level.

A self-contained, battery powered transseptal crossing system is disclosed. An elongate, flexible electrically conductive needle body has a proximal end and a distal end. An insulation layer surrounds the sidewall and leaves exposed a distal electrode tip. A generator is configured to deliver RF energy to the electrode tip, and includes a processor configured to take impedance measurements at the tip to confirm contact with the intra atrial septum and/or confirm entry into the left atrium.

Adjacent tissue layers can be accessed using a catheter device with a distal tip having a conductive portion including a first cutting feature and one or more projections extending from the first cutting feature towards an outer diameter of the distal tip. Electrical energy can be supplied to the conductive portion of the device to cut tissue. A stent can be delivered to form a fluid communication between the adjacent tissue layers.

An instrument and method for tissue thermotherapy including an inductive heating means to generate a vapor phase media that is used for interstitial, intraluminal, intracavity or topical tissue treatment. In one method, the vapor phase media is propagated from a probe outlet to provide a controlled vapor-to-liquid phase change in an interface with tissue to thereby apply ablative thermal energy delivery.

Ablation systems and methods detect and address distortion caused by a variety of factors. A method includes measuring a temperature curve at target tissue; applying ablation energy to the target tissue; determining a peak temperature on the temperature curve; if the peak temperature is greater than the predetermined peak temperature, determining a time at which the temperature curve crosses to a lower temperature; and if the determined time is greater than a predetermined time, generating a message indicating that the target tissue was successfully ablated. Another method includes determining a distance between a remote temperature probe and an ablation probe, applying ablation energy to target tissue, measuring temperature at the remote temperature probe, estimating ablation size based on the determined distance and the temperature measured by the remote temperature probe, and determining whether the target tissue is successfully ablated based on the estimated ablation size.